Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Sleep  COVID-19 treatment studies for Sleep  C19 studies: Sleep  Sleep   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Severe case 19% Improvement Relative Risk Severe case (b) 26% c19early.org/sl Zhang et al. Sleep for COVID-19 Prophylaxis Favors good sleep Favors control
Association of sleep quality before and after SARS-CoV-2 infection with clinical outcomes in hospitalized patients with COVID-19 in China
Zhang et al., EXCLI Journal; 20:Doc894; ISSN 1611-2156, doi:10.17179/excli2021-3451
14 May 2021    Source   PDF   Share   Tweet
Prospective study of 205 hospitalized COVID-19 patients in China, showing higher risk of severe cases with poor sleep quality.
risk of severe case, 18.7% lower, HR 0.81, p < 0.001, inverted to make HR<1 favor higher quality sleep, global PQSI before infection, Cox proportional hazards, model 3.
risk of severe case, 25.9% lower, HR 0.74, p = 0.007, inverted to make HR<1 favor higher quality sleep, global PQSI after infection, Cox proportional hazards, model 3.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
This study is excluded in meta analysis: results only provided with respect to continuous values.
Zhang et al., 14 May 2021, prospective, China, peer-reviewed, survey, mean age 58.0, 15 authors, study period 6 January, 2020 - 9 March, 2020.
Contact: rongshuang@wust.edu.cn, wei-bao@uiowa.edu.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperSleepAll
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit